JMP Securities Starts Epizyme (EPZM) at Market Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to JMP Securities Starts Epizyme (EPZM) at Market Outperform
June 26, 2013 4:49 PM EDT
Wedbush initiated coverage on Epizyme (NASDAQ: EPZM) with an Outperform rating and a price target of $37.00.
"Advances in genetically defining sub-sets of cancer patients have identified members of the family of histone methyltransferase (HMT) proteins as key drivers of malignancy. . .... More
June 25, 2013 10:32 AM EDT
Cowen initiates coverage on Epizyme (NASDAQ: EPZM) with a Outperform.
For an analyst ratings summary and ratings history on Epizyme click here. For more ratings news on Epizyme click here.
Shares of Epizyme closed at $27.55 yesterday, with a 52 week range of $18.60-$30.86.... More
June 25, 2013 7:50 AM EDT
Leerink Swann initiates coverage on Epizyme (NASDAQ: EPZM) with a Outperform. PT $34.00.
For an analyst ratings summary and ratings history on Epizyme click here. For more ratings news on Epizyme click here.
Shares of Epizyme closed at $27.55 yesterday, with a 52 week range of $18.60-$30.86.... More
June 25, 2013 7:12 AM EDT
Citi initiates coverage on Epizyme (NASDAQ: EPZM) with a Buy. PT $32.00.
For an analyst ratings summary and ratings history on Epizyme click here. For more ratings news on Epizyme click here.
Shares of Epizyme closed at $27.55 yesterday, with a 52 week range of $18.60-$30.86.... More
